James G McCormack Selected Research

eptapirone

3/2009

5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

James G McCormack Research Topics

Disease

3	Type 2 Diabetes Mellitus (MODY) 04/2008 - 08/2002
1	Hypertension (High Blood Pressure) 03/2009
1	Tachycardia (Tachyarrhythmias) 03/2009
1	Weight Loss (Weight Reduction) 03/2009
1	Obesity 04/2008
1	Body Weight (Weight, Body) 04/2008
1	Insulin Resistance 03/2003

Drug/Important Bio-Agent (IBA)

1	eptapironeIBA 03/2009
1	sibutramine (Meridia)FDA Link 03/2009
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 03/2009
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 03/2009
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 04/2008
1	Blood Glucose (Blood Sugar)IBA 04/2008
1	Adenosine Triphosphate (ATP)IBA 03/2003
1	Proteins (Proteins, Gene)FDA Link 03/2003
1	EnzymesIBA 03/2003
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 03/2003
1	ProteomeIBA 03/2003
1	Creatine Kinase (Creatine Phosphokinase)IBA 03/2003
1	Glycogen Phosphorylase (Phosphorylase, Glycogen)IBA 08/2002

Therapy/Procedure

1	Glycemic Control 04/2008
1	Injections 04/2008